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Abstract
Rationale Impairments in behavioral flexibility lie at the core
of anxiety and obsessive-compulsive disorders. Few studies,
however, have investigated the neural substrates of natural
variation in behavioral flexibility and whether inflexible be-
havior is linked to anxiety and peripheral markers of stress and
monoamine function.
Objective The objective of the study was to investigate pe-
ripheral and central markers associated with perseverative be-
havior on a spatial-discrimination serial reversal learning task.
Methods Rats were trained on a reversal learning task prior to
blood sampling, anxiety assessment, and the behavioral eval-
uation of selective monoamine oxidase-A (MAO-A) and
MAO-B inhibitors, which block the degradation of serotonin
(5-HT), dopamine (DA), and noradrenaline (NA).
Results Perseveration correlated positively with 5-HT levels
in blood plasma and inversely with trait anxiety, as measured
on the elevated plus maze. No significant relationships were
found between perseveration and the stress hormone cortico-
sterone or the 5-HT precursor tryptophan. Reversal learning
was significantly improved by systemic administration of the
MAO-A inhibitor moclobemide but not by the MAO-B inhib-
itor lazabemide. Moclobemide also increased latencies to ini-
tiate a new trial following an incorrect response suggesting a
possible role in modulating behavioral inhibition to negative
feedback. MAO-A but not MAO-B inhibition resulted in pro-
nounced increases in 5-HTandNA content in the orbitofrontal
cortex and dorsal raphé nuclei and increased 5-HT and DA
content in the basolateral amygdala and dorsomedial striatum.
Conclusions These findings indicate that central and periph-
eral monoaminergic mechanisms underlie inter-individual
variation in behavioral flexibility, which overlaps with trait
anxiety and depends on functional MAO-A activity.
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Introduction
Behavioral inflexibly is common to a range of compulsive and
anxiety-related brain disorders, including addiction,
obsessive-compulsive disorder (OCD), and schizophrenia
(Fineberg et al. 2010; Robbins et al. 2012; Voon et al. 2015).
Elucidating the neural and psychological mechanisms of be-
havioral inflexibility is therefore important to facilitate the
diagnosis and treatment of a range of mental disorders.
Based on selective brain intervention studies, much is known
about the neural mechanisms underlying one aspect of im-
paired behavioral flexibility, namely excessive perseveration
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in response to shifts in the stimulus-reward contingency of
reversal learning paradigms (Castane et al. 2010; Rygula
et al. 2010). However, few studies have investigated the neural
mechanisms of inter-individual differences in behavioral flex-
ibility and how these relate to anxiety and other traits present
in OCD and related disorders.
Convergent evidence indicates that serotonin (5-HT) mod-
ulates reversal learning in a number of species (Roberts 2006).
As reviewed by Izquierdo et al. (2016), elevated post synaptic
5-HT activity facilitates reversal learning (Bari et al. 2010;
Barlow et al. 2015; Danet et al. 2010; Wallace et al. 2014)
whereas reduced 5-HTsignaling impairs reversal learning and
increases perseveration (Clarke et al. 2005, 2007; Lapiz-
Bluhm et al. 2009; Rygula et al. 2015). In a similar manner,
selective 5-HT2A and 5-HT2C receptor antagonists, respective-
ly, impair and improve reversal learning (Boulougouris et al.
2008) with the orbitofrontal cortex (OFC) an important locus
for the latter beneficial effects (Boulougouris and Robbins
2010), consistent with much previous evidence implicating
the OFC in reversal learning (Boulougouris et al. 2007; Dias
et al. 1996; Schoenbaum et al. 2009; Stalnaker et al. 2009).
Functionally, 5-HT in this region is hypothesized to inhibit
actions to previously rewarded stimuli when aversive or neg-
ative outcomes are expected (Cools et al. 2011; Roberts 2011).
We recently reported in outbred rats that excessive persev-
eration on an appetitive, spatial reversal learning task is asso-
ciated with diminished 5-HTmetabolism and 5-HT2A receptor
availability in the OFC, as well as altered gene expression of
the two isoforms of monoamine oxidase, MAO-A and MAO-
B, in the dorsal raphé nucleus (DRN) and OFC (Barlow et al.
2015). In the present study, we extended these findings by
investigating the causal involvement of MAO-A and MAO-
B in mediating reversal learning performance. We reasoned
that since MAO-A has a high affinity for 5-HT and norepi-
nephrine (NE), unlikeMAO-B (Da Prada et al. 1988; Shih and
Thompson 1999), selective MAO-A inhibition by
moclobemide would improve behavioral flexibility. We ex-
tended our analysis to the measurement of 5-HT in blood
samples since MAO inhibition produces parallel increases in
5-HT levels in the brain and blood (Malyszko et al. 1993),
similar to the effects of psychostimulants and selective 5-HT
reuptake inhibitors (Zolkowska et al. 2006). In addition, plate-
let MAO activity has been proposed as an index of central 5-
HT activity (Stahl 1985) and low activity of this enzyme has
been associated with OCD severity (Arrojo et al. 2007). Thus,
the peripheral measurement of unbound 5-HT may be an ac-
cessible marker of central 5-HT transmission, under some
circumstances, and reflect inter-individual differences in be-
havioral flexibility. We also measured levels of the 5-HT pre-
cursor tryptophan, as well as circulating levels of the stress
hormone corticosterone. Subsequently, we used a factor anal-
ysis to relate these levels to trait anxiety and perseverative
errors on a spatial reversal learning task (Barlow et al. 2015).
The primary objective of the present study was to clarify
the extent to which individual variation in behavioral flexibil-
ity on a spatial-discrimination serial reversal learning task can
be explained by peripheral biomarkers and trait anxiety and to
relate these trait markers to levels of 5-HT and other mono-
amines in key brain loci implicated in reversal learning, in-
cluding the OFC, basolateral amygdala (BLA), and striatum
(Izquierdo et al. 2013; Ochoa et al. 2015).
Methods
Subjects
Male Lister-hooded rats (n = 48) weighing 290 ± 17 g at the
beginning of experiments were used (Charles River, Kent,
UK). They received 18 g of laboratory chow once a day with
ad libitum access to water. The weight of each animal was
recorded each week with animals maintained at 85–95% of
free-feeding weights. When no behavioral training or testing
took place, rats received 20 g of chow per day. All animals
were housed in groups of four per cage and kept under a
reversed 12 h light/dark cycle (lights off 07:00 h until
19:00 h). Rats were trained on the spatial reversal learning
task between 14:00 and 19:00 h. Testing on the elevated plus
maze (EPM) and the collection of blood samples took place
between 15:30 and 16:30 h. Five rats were excluded from the
study because they failed to reach criterion on the reversal
learning task. One further animal developed audiogenic sei-
zures and therefore was culled before drug challenge. Forty-
two animals received systemic drug injections, of which 19
animals were used for region-specific post mortem mono-
amine analysis to validate the effects of moclobemide and
lazabemide (Fig. 1a). Three other animals failed to complete
the task after drug administration and therefore were excluded
from further analysis. Experiments complied with the UK
Animals (Scientific Procedures) Act of 1986 and were ap-
proved by the ethics review committee at Cambridge
University.
Behavioral apparatus
Twelve five-hole operant chambers (Med Associates,
Georgia, VT) controlled by two computers and Whisker
Control software (Cardinal and Aitken 2010) were used
(Fig. 1b). Each chamber was enclosed in a ventilated sound-
attenuating box, fitted with five apertures in a curved wall and
a food magazine on the opposite wall of the box that delivered
rodent sugar pellets (TestDiet®, Purina, UK). A yellow light-
emitting diode stimulus was placed at the rear of each aper-
ture. The middle three apertures were blocked using a metal
plate and were not part of the experimental setup. The food
magazine and entire chamber was illuminated by light
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emitting diodes. Infrared beams detected responses in the
magazine and apertures.
The elevated plus maze was constructed from black
Perspex and consisted of a central platform surrounded by
two open arms and two enclosed arms in the shape of a plus
sign (Molander et al. 2011; Walf and Frye 2007). The plus-
shaped platform was elevated 60 cm above the floor in a room
illuminated by white light (intensity 70 lx). Exploratory be-
havior in the maze was recorded and monitored on a ceiling-
mounted Yi Action Camera connected wirelessly to a
computer.
Behavioral training
Training began with 2 days of habituation during which ani-
mals were exposed to the testing boxes with all cue lights,
magazine, and house lights on for 20 min. They were encour-
aged to explore the apparatus by baiting the response apertures
and magazine with sugar pellets. Before the start of each ses-
sion, all lights were extinguished. The first trial was initiated
by the animal making a nose-poke in the magazine, which
triggered the illumination of a cue light in each aperture.
Responding in either aperture was initially reinforced by the
delivery of a single food pellet. Task difficulty was then pro-
gressively increased with just one aperture reinforced (the
Bcorrect^ aperture) under FR1, FR2, and FR3 schedules (see
Table 1). Finally, the inter-trial interval (ITI) was gradually
increased from 1 to 2 s and finally to 5 s upon completion of
the previous stage. For all training stages, a criterion of 50
correct trials was required to proceed to the next level.
While the FR1-FR3 stages were restricted to 20 min, session
times increased to 30 min for the ITI stages. If a subject made
an incorrect response at the non-cued aperture, it was not
penalized during training. However, a failure to make the ap-
propriate response within 30 s of initiating a new trial was
recorded as an omission and was followed by a 5-s time-out
where all lights were turned off.
In the spatial-discrimination task, the training setup above
was modified with both apertures lit but with only one of
apertures rewarded. Three nose-pokes in the Bincorrect^ aper-
ture now resulted in the omission of reward and a 5 s time-out.
Rats were given 1 h to complete the discrimination task by
achieving 9 correct trials across previous 10 trials. If animals
failed to achieve criterion after 2 days, they were retrained by
completing the 5-s ITI condition within a single session.
On the day following the completion of the discrimination
task, animals experienced the same configuration of the task,
whereby the correct aperture was kept the same on both days
as a measure of retention (Fig. 1b). Once the 9/10 criterion
was achieved, the previously correct aperture was no longer
rewarded and the rat was required to respond in the other
aperture to obtain reward. Similar to the discrimination
Fig. 1 a Experimental timeline and group sizes. Blood samples were
extracted before and after training on the reversal learning task followed
by anxiety testing and the behavioral and neurochemical evaluation of
MAO inhibition. b Schematic depiction of the spatial-discrimination
reversal learning task. Rats initiated each session by making a nose-
poke response in the food magazine (1). By making nose-poke
responses in the Bcorrect^ aperture under a fixed-ratio-3 schedule of
reinforcement, a food pellet was delivered in the illuminated magazine
(2-3c; 4b), followed by a 5-s time-out (5). BIncorrect^ responses and
failure to respond (Bomissions^) resulted in a 5-s time-out (4a). If the
rat achieved nine correct responses over the previous 10 trials, the
reward contingencies were switched such that the rat now needed to
respond at the previously unrewarded aperture. Each animal completed
three reversals within a 1-h session
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condition, an incorrect response or an omission resulted in a
5 s time-out. Subjects could complete up to three reversals
during the 1-h session.
Elevated plus maze
Animals were habituated to the experimental room for 30 min
in their home cage before testing commenced. Each rat was
placed on the central platform facing an open arm. The maze
was thoroughly cleaned with water and dried between each
test. Recordings during the first 6 min on the EPM were man-
ually scored, specifically to record the time spent in the open
arms and the number of entries made into the open arms, as
described previously (Walf and Frye 2007).
Systemic drug administration
Forty-two animals received mock injections 2 days before the
start of the administration of the selective, reversible MAO-A
and MAO-B inhibitors (moclobemide and lazabemide, re-
spectively). Moclobemide and lazabemide hydrochloride
were purchased from Tocris (UK) and dissolved in 15%
hydroxypropyl-beta-cyclodextrin and 0.9% saline
(Bvehicle^). Moclobemide was fully dissolved using repeated
sonication at +35 °C. Following the ranking of the animals by
their reversal learning performance, two groups of animals
were formed, matched for the number of perseverative errors
made, and each assigned to one of the two MAO inhibitors.
Given the relatively short washout periods for the drugs (Da
Prada et al. 1988), each animal received four separate treat-
ments across 3-day intervals, starting with a baseline retention
session (day 1), a drug administration session (day 2), and a
drug-free day. Doses for moclobemide (3 and 16 mg/kg, com-
bination of 10 mg/kg of moclobemide and 10 mg/kg
lazabemide) and lazabemide (1 and 10 mg/kg) were selected
on the basis of previous literature (Da Prada et al. 1988;
Jolkkonen et al. 2000; Kitaichi et al. 2006, 2010; Maki et al.
2000) and administered intraperitoneally (1 ml/kg). The
dosing regimen followed a randomized modified Latin square
design to control for training and crossover effects. One hour
after the drug (or vehicle) injections, subjects were assessed
for reversal learning performance.
In order to validate the effects of moclobemide and
lazabemide on monoamine levels, 19 animals were matched
for baseline performance and drug history and subsequently
divided into three groups: a vehicle control group (15% HPB,
n = 5), a lazabemide group (10 mg/kg, n = 6), and a
moclobemide group (16 mg/kg, n = 4 and 3 mg/kg, n = 4)
groups. Consistent with the timing of previous testing condi-
tions, animals were culled for ex vivo neurochemical analysis
1 h after each injection.
Blood analyses
Sublingual blood samples were collected in isoflurane-
anesthetized animals (2.5% isoflurane in 95% O2, 5% CO2).
Approximately 1 ml of blood was collected in tubes primed
with ethylenediaminetetraacetic acid (EDTA), cooled on dry
ice, and centrifuged at 3000×g for 20 min at 4 °C. Supernatant
plasma was aliquoted in separate tubes for monoamine quan-
tification using high-performance liquid chromatography
(HPLC) with electrochemical detection (ECD). Plasma corti-
costerone was quantified by radioimmunoassay (Carter et al.
2004) using a citrate buffer at pH 3.0 to denature the
corticosteroid-binding globulin and a specific corticosterone
antibody (kindly supplied by G. Makara, Institute of
Experimental Medicine, Budapest, Hungary), as previously
described in detail (Atkinson et al. 2006; Windle et al. 1998).
Monoamine analysis
Plasma samples were diluted 1:20 in 0.2 M perchloric acid, and
centrifuged at 10,000 rpm at 4 °C for 20 min. Twenty-five mi-
croliters of the supernatant was injected onto the HPLC-ECD
system to measure levels of 5-HT, 5-hydroxyindoleacetic acid
(5-HIAA), tryptophan, and noradrenaline (NA), as described
Table 1 Summary of the training procedure for the acquisition of the spatial-discrimination task and subsequent reversals of the stimulus-reward
response contingency
Stage Total time
(min)
Time-out period Criterion Cues
Habituation 20 None Eat all pellets in box All lights on
FR1 pre-training 20 None 50 pellets Both sides cued and rewarded
FR1, FR2, FR3 training 20 30 s 50 pellets Only one side cued
1 s, 2 s, 5 s ITI training 30 None for 1 s ITI,
otherwise 30 s
50 pellets Only one side cued
Spatial-discrimination 60 30 s 9/10 correct on one side Both sides cued
Reversal test 60 30 s Three reversals, i.e., 9/10
correct on 4 sides
Both sides cued
FR fixed ratio, ITI inter-trial interval
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previously (Dalley et al. 2002). Detection and quantification
were achieved using a Coulochem II detector with an analytical
cell and two electrodes in series (E1 −250 mV, E2 +250 mV).
The signal from E2 was integrated using computer software
(Chromeleon, Dionex, UK).
One hour after drug injection, animals were killed by as-
phyxiation in a rising concentration of CO2 (n = 19). Brains
were rapidly removed and flash frozen in liquid nitrogen,
placed on dry ice, and stored at −80 °C. They were later cut
into 150 μm coronal sections on a Jung CM300 cryostat
(Leica, Wetzlar, Germany) and stored at −80 °C. At room
temperature, small aliquots of tissue were removed bilaterally
from two consecutive sections from the dorsomedial prefron-
tal cortex (dmPFC), OFC, DRN, hippocampal CA1 area, lat-
eral hypothalamus (LH), BLA, dorsomedial striatum (dmS),
and nucleus accumbens (NAcb) using a micropunch of diam-
eter 1.0 mm (Fig. 6e). More details of this procedure can be
found in Palkovits (1973). Samples were homogenized in
60 μl of 0.2 M perchloric acid using an ultrasonic cell
disruptor, spun at 6000 rpm for 20 min (4 °C), and analyzed
for 5-HT, NA, DA, 5-HIAA, and 3-4 dihydroxyphenylacetic
acid (DOPAC). Monoamine levels were quantified in 25 μl of
the homogenized brain samples using HPLC-ECD, as de-
scribed above.
Statistical analyses
Statistical analyses were conducted using SPSS for
Windows (IBM version 23). Perseveration was assessed
using the total number of trials and errors made until
subjects achieved criterion. Errors were considered per-
severative in nature if in a window of 10 trials, 7 incorrect
responses were made. The number of perseverative errors
made during the three reversals was used to rank the an-
imals, consistent with (Barlow et al. 2015). Based on this
ranking, three groups were formed that included highly
perseverative (n = 11), mid-range (n = 20), and low-
perseverative animals (n = 11). One of the low-
perseverative rats and two of the mid-range rats were un-
able to complete the task in drug conditions and had to be
excluded (Table 2). A mixed effects ANOVA was used to
analyze within-subject effects of the drugs and between-
subject effects of group as well as their interactions
following systemic drug administration. Partial eta-
squared (η2) was used to assess effect size. A two-way
between-subject ANOVA was used to compare the effects
of the drugs on monoamine levels in the brain. If spheric-
i ty was violated (signif icant Mauchly ’s test) , a
Greenhouse-Geisser correction was used. When signifi-
cant main effects or interactions were found, post hoc
analyses were carried out using Fisher’s LSD tests and
the calculation of effect size η2.
To identify markers of perseveration and anxiety, a factor
analysis model was used. Since several variables were posi-
tively skewed and significantly non-normal, principal axis
factoring was chosen as the integration method (Costello
and Osborne 2005). Further, since the extracted factors did
not correlate well with each other, the orthogonal rotation
method (varimax) was preferred. Most errors made by the
animals were perseverative; hence, only those were included
to avoid excessive multicollinearity. Factor analysis variables
included perseverative errors, total trials to criterion, and plas-
ma levels of neurochemicals and corticosterone, alongside
measures of trait anxiety (proportion of time spent in open
arms of the EPM and percentage of open arm entries).
Proportions were the preferred dependent variable to control
for general locomotor activity (Walf and Frye 2007).
Inferential contrasts were considered statistically significant
at α = 0.05.
Results
Means ± SEM perseverative errors were 36.3 ± 2.6 for high-
perseverative animals, 19.6 ± 1.0 for the mid-range group and
7.3 ± 0.79 for the low-perseverative group.Within these high-,
mid- and low-perseverative groups, the total number of errors
(mean ± SEM: 58.9 ± 4.3, 37.6 ± 2.1, 31.5 ± 2.2, respectively)
and total trials to criterion (mean ± SEM: 137.3 ± 10.3,
104.9 ± 6.0, 101.5 ± 6.5, respectively) followed the distribu-
tion of perseverative errors (Fig. 2). Prior to training, persev-
erative errors, total errors, and total trials to criterion as well as
concentrations of peripheral NA, 5-HIAA, 5-HT, and trypto-
phan were positively skewed (skewness 0.82, 1.01, 0.97,
3.627, 1.0, 1.72, and 2.048, respectively). 5-HT and NE dis-
tributions remained skewed after training (1.70 and 0.73, re-
spectively), similar to corticosterone levels and the 5-HT/5-
HIAA ratio (1.71 and 1.52). Other variables were less skewed,
as indicated by values below 0.7.
Increased perseveration is associated with decreased
anxiety and plasma 5-HT levels
Factor analysis was used to investigate the correlative relation-
ships between plasma monoamine levels and task perfor-
mance. Following the Kaiser criterion, all five factors with
Table 2 Final group sizes for animals that successfully completed the
task under drug conditions
Moclobemide Lazabemide
Perseveration rank High Mid Low High Mid Low
Group size 5 9 4 6 9 6
Total size 18 21
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eigenvalues greater than one were extracted and orthogonally
rotated that jointly accounted for over 58.2% of the variance in
the data (Fig. 3). The first factor featured the two anxiety
measures as well as perseverative errors. The second factor
included pre-training levels of NA, 5-HIAA, tryptophan, and
corticosterone. The third factor, accounting for 11.9% of var-
iance, included perseveration, plasma levels of 5-HT, and the
5-HT/5-HIAA ratio. Corticosterone levels and post training
levels of NA were loaded on factor 4 whereas post training
levels of 5-HIAA and 5-HTwere loaded on factor 5. Factors 4
and 5 jointly explained 8% of the variance.
Linear regression models were then created to inves-
tigate the strength of associations between perseveration,
anxiety measures, and peripheral biomarkers. As shown
in Fig. 3, a positive relationship was found between the
proportion of entries into the open arms of the EPM
and the perseverative errors (F1,43 = 7.82 r = 0.39,
p = 0.008). Reflecting the loadings on the third factor,
a significant correlation was found between persevera-
tive errors and pre-training levels of 5-HT in the plasma
(F1,43 = 4.27, r = 0.31, p = 0.045).
MAO-A inhibition but not MAO-B inhibition improves
reversal learning
The effects of MAO-A and MAO-B inhibition on reversal
learning performance are shown in Fig. 4. As no interactive
effects were found between the effects of moclobemide and
perseveration group on total trials, errors, or proportion of
perseverative errors (F6,45 = 1.32, p = 0.27; F6,45 = 0.40,
p = 0.88, F6,45 = 0.84, p = 0.55, respectively), these were
collapsed across perseveration group for subsequent analy-
ses. This analysis revealed that moclobemide significantly
improved reversal learning performance, as indexed by total
trials to criterion (F3,45 = 11.27, p < 0.0001, η
2 = 0.429;
Fig. 4a). Both the high and the low doses of moclobemide,
as well as the combination of moclobemide and lazabemide,
produced significant improvements compared with the vehi-
cle group, as revealed by post hoc comparisons (p < 0.001,
η2 = 0.606; p < 0.0001, η2 = 0.677; p < 0.002, η2 = 0.486,
respectively).
With respect to the lazabemide group, only the combined
dose decreased the number of trials to achieve criterion
Fig. 2 a Factor loadings (all loadings >0.3 are displayed). b Correlation matrix of all variables in the factor analysis, including peripheral monoamines,
corticosterone, and behavioral measures
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(F3,60 = 3.33, p < 0.025, η
2 = 0.143; Fig. 4b). No significant
interactive effects of lazabemide and perseveration group
were observed on this measure. The combination of
moclobemide and lazabemide decreased the number of trials
to criterion comparedwith the high (p = 0.046, η2 = 0.184) and
low doses (p = 0.033, η2 = 0.209) of lazabemide and the
Fig. 4 Effects of moclobemide
(n = 18) and lazabemide (n = 21)
on total trials to achieve criterion
(a, b) and the proportion of
perseverative errors (c, d). Mean
values ± SEM for a single post
drug administration session are
shown. Significance is denoted as
follows: *p < 0.05, **p < 0.01,
***p < 0.001 versus vehicle
Fig. 3 a Distribution of
perseverative errors on the spatial-
discrimination reversal learning
task expressed as percentage of
the cohort size (n = 45). b
Perseverative errors were
significantly correlated with the
proportion of time spent in the
open arms of the elevated plus
maze (r2 = 0.154, p = 0.008). c
Lack of a significant relationship
between perseverative errors and
blood corticosterone levels
(r2 = 0.096, p = 0.064). d Positive
relationship between the plasma
concentration of 5-HT (in fmoles/
μl) and the perseverative errors
(r2 = 0.096, p = 0.045)
Psychopharmacology
vehicle group (p = 0.023, η2 = 0.234). Lazabemide itself had
no significant effects on total trials to criterion.
Analysis of total errors mirrored the effects of
moclobemide and lazabemide on total trials to criterion.
Thus, one-way repeated measures ANOVA revealed signifi-
cant main effects of drug treatment (moclobemide
F3,45 = 7.51, p = 0.0001, η
2 = 0.344; lazabemide
F3,54 = 4.83, p = 0.005, η
2 = 0.212); post hoc analyses iden-
tified significant effects of high and low doses of
moclobemide, as well as the drug combination, to decrease
the total number of errors compared with the vehicle group
(p = 0.001, η2 = 0.542; p = 0.001, η2 = 0.535; p = 0.01,
η2 = 0.367, respectively). The combination of both drugs sig-
nificantly decreased the total number of errors to criterion
compared to the high and low dose of lazabemide and vehicle
(p = 0.021, η2 = 0.261; p = 0.01, η2 = 0.313; p = 0.004,
η2 = 0.383). No interactions between lazabemide and group
were found (F6,54 = 0.25, p = 0.96) nor did lazabemide itself
have any effects on behavioral performance.
By contrast, moclobemide decreased the proportion of per-
severative errors (F3,45 = 3.86, p = 0.016 η
2 = 0.216; Fig. 4c)
with the highest dose significantly reducing perseverative er-
rors compared with the vehicle group (p = 0.003, η2 = 0.428).
As shown in Fig. 4d, no main effects or interactions were
observed with respect to lazabemide on the proportion of per-
severative errors (F3,51 = 0.72, p = 0.55, F6,51 = 0.37, p = 0.90,
respectively).
MAO-A inhibition increases the latency to initiate a new
trial following an incorrect response
Latencies to initiate a new trial following incorrect and correct
responses are shown in Fig. 5. Mixed effect ANOVA with
treatment as a within-subject factor and latency type as a
between-subject factor revealed a significant difference in
the pattern of effects produced by the drug treatment on cor-
rect and incorrect responses in the moclobemide group (treat-
ment × latency type interaction F3,87 = 5.74, p = 0.001,
η2 = 0.165) but not in the lazabemide group (F3,87 = 1.81,
p = 0.150). Repeated measures ANOVA revealed a significant
main effect of dose for the moclobemide group (F3,45 = 7.514,
p = 0.011, η2 = 0.334; Fig. 5a) with the highest dose
prolonging incorrect response latencies compared with the
vehicle group (p = 0.004, η2 = 0.440), combination treatment
(p = 0.038 η2 = 0.258) and the low dose of moclobemide
(p = 0.013, η2 = 0.345). In addition, incorrect response laten-
cies following the combined drug injections were significantly
longer than those following a low dose of moclobemide
(p = 0.024, η2 = 0.297). A similar pattern of results was ob-
tained for the lazabemide group (main effect of dose
F3,57 = 5.622, p = 0.002 η
2 = 0.228; Fig. 5b) with the drug
combination again lengthening incorrect response latencies
compared with the vehicle group (p = 0.012 η2 = 0.287).
A different pattern of results was observed with respect to
the effects of MAO-A and MAO-B inhibition on correct re-
sponse latencies. No significant differences were found in the
MAO-A group (F3,45 = 2.164, p = 0.105; Fig. 5c), while
correct response latencies in the MAO-B group were signifi-
cantly variable between the different drug groups
(F3,57 = 13.523, p = 0.0001, η
2 = 0.416; Fig. 5d). A combina-
tion of both drugs increased the time to initiate a new trial
following a correct response compared with the vehicle group
(p = 0.0001, η2 = 0.489).
MAO-A inhibition facilitates a lose-shift strategy in highly
perseverative animals only
A repeated measures ANOVA with treatment as within-
subject factor and baseline perseveration (high versus low
perseveration) as between-subject factor revealed a significant
main effect of drug (F3,24 = 5507, p = 0.005, η
2 = 0.408) and a
significant interactive effect of treatment with the probability
of changing a response after a loss trial (F3,24 = 3373,
p = 0.035, η2 = 0.297). Mean lose-shift probabilities indicated
that moclobemide selectively increased the probability of
shifting compared with vehicle or combination treatment after
a loss trial in highly perseverative but not low-perseverative
animals (Table 4). No other significant effects of drug treat-
ment on the win-stay or lose-shift probabilities were observed
(all p values >0.05).
MAO-A inhibition strongly increases 5-HT and NE
content in OFC, DRN and BLA
The effects of selective MAO-A and MAO-B inhibition on
brain monoamine content are shown in Fig. 6 and Table 3. For
each chemical neuromodulator, a separate ANOVA model
was tested. A two-way ANOVA with drug treatment and re-
gion as between-subject factors revealed significant main ef-
fects of treatment (F3,119 = 82.17, p < 0.0001, η
2 = 0.627) with
respect to 5-HT levels. Post hoc analyses of main effects
(LSD) show that across all regions of interest, 5-HT levels
were significantly higher following both high (16 mg/kg)
and low (3 mg/kg) doses of moclobemide than following
lazabemide or vehicle injections (all p < 0.0001). Notably,
lazabemide did not increase 5-HT levels compared with the
vehicle group (p = 0.6). However, the increase in 5-HTcontent
induced by moclobemide was not uniform across all regions,
as revealed by a significant treatment by region interaction
(F21,119 = 15.92, p < 0.0001, η
2 = 0.738). As shown in
Fig. 6 and Table 3, average 5-HT levels increased 35 ± 10-
fold (±CI0.95) following a high dose of moclobemide com-
pared to vehicle in the OFC, 30 ± 13-fold in the DRN,
27 ± 17-fold in the lateral hypothalamus, 9 ± 4-fold in the
BLA, and 4 ± 1-fold in the dorsomedial striatum.
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MAO inhibition also produced significant changes in DA
and NA content (F3,118 = 33.70, p < 0.0001, η
2 = 0.461;
F3,120 = 29.69, p < 0.0001, η
2 = 0.426, respectively), with
moclobemide significantly increasing DA and NA levels
compared with both the vehicle and lazabemide groups (all
p values <0.0001). However, DA and NA increases were not
uniform across all areas, as indicated by the significant inter-
action between region and treatment (F3,90 = 28.80,
p < 0.0001, η2 = 0.490; F15,90 = 5.791, p < 0.0001,
η2 = 0.491, respectively). Strongest increases in average DA
levels (11-fold) were found in the lateral hypothalamus, with
up to 5-fold increases in other regions, including a 2-fold
increase in the striatum (Fig. 6; Table 3). Similarly, 3-fold
increases in NAwere found in the OFC and DRN and up to
2-fold increases in other brain regions. MAO-B inhibition did
not significantly affect 5-HT, DA, or NA levels compared to
the vehicle treatment as revealed by post hoc contrasts
(p = 0.60, p = 0.06, p = 0.24, respectively).
Discussion
The main findings of this investigation indicate that behavior-
al inflexibility, as measured by perseverative responding on a
spatial reversal learning task, is multidimensional and linked
to reduced anxiety and increased levels of circulating plasma
5-HT prior to behavioral training. Inflexible behavior on this
task was significantly improved by MAO-A inhibition, but
not by MAO-B inhibition, and was accompanied by strong
increases in 5-HTand NE levels in the OFC, DRN, and BLA,
as well as longer latencies to initiate a new trial following an
incorrect, but not a correct response. These findings collec-
tively indicate that inter-individual variation in behavioral
flexibility correlates with low trait anxiety and peripheral mea-
sures of serotonergic function and is strongly and selectively
modulated by MAO-A inhibition, which putatively may have
the effect of strengthening behavioral inhibition in response to
recent negative feedback.
Animals exhibiting high levels of perseverative responding
during reversals of the instrumental contingency were less
anxious on the elevated plus maze than low perseveration
animals. At first glance, this finding appears to run counter
to traditional views that anxiety relief is an important driver
for maintaining compulsive behavior in OCD. However, al-
though obsessions and compulsions may be accompanied by
anxiety symptoms, and worsened by stress, a prominent caus-
al role of anxiety in OCD for compulsive behavior is contro-
versial and not widely accepted (Fineberg et al. 2010;
Hollander et al. 2008; Stein et al. 2010). Moreover, to our
knowledge, no studies have hitherto reported the direct rela-
tionship between trait-like variation in anxiety and behavioral
flexibility in rodents. Nevertheless, consistent with the present
study, high trait-like anxiety in marmoset monkeys has been
associated with a tendency for improved flexibility on tasks
that depend on the anterior OFC and ventrolateral PFC (Shiba
et al. 2014). The explanation for the apparent inverse
Fig. 5 Effects of moclobemide
(n = 16) and lazabemide (n = 20)
on response latencies (s)
following an incorrect (a, b) and
correct (c, d) response. Data for
two animals was not saved due to
a technical failure with the
equipment. *p < 0.05, **p < 0.01,
***p < 0.001 versus vehicle
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relationship between perseveration and trait anxiety is unclear
but may be related to increased vigilance and/or enhanced
sensitivity of highly anxious subjects to negative environmen-
tal cues and feedback (Bradley et al. 1999; Cisler and Koster
2010). Thus, following a shift in the stimulus-response (S-R)
contingency, subjects exhibiting increased anxiety may be less
likely to perseverate because their attention is drawn to the
previously incorrect (i.e., non-reinforced) stimulus and
through increased exploration more readily detect changes in
the S-R contingency (Homberg and Lesch 2011). This hy-
pothesis suggests that low-anxious, highly perseverative rats
may disregard negative feedback in preference for positive
stimuli, and this may be relevant to the beneficial effects of
MAO-A inhibition on behavioral flexibility.
A small but significant component of the variance in per-
severation was accounted for by plasma levels of 5-HT mea-
sured prior to training on the reversal learning task. No asso-
ciations were found for circulating levels of the 5-HT precur-
sor tryptophan or hormones linked to stress and the
hypothalamic-pituitary adrenal axis (NE and corticosterone).
While the latter markers provide further separation between
perseveration and anxiety and stress responses, our
Fig. 6 Effects of selective MAO
inhibition onmonoamine levels in
a OFC, b DRN, c BLA, and d
dorsomedial striatum (pmol/mg
tissue). In c and d, dopamine
levels are shown on the left y-axis
while NA and 5-HT levels are
shown on the right y-axis. Data
are mean values ± SEM.
Significance is denoted as
follows: *p < 0.05, **p < 0.005
versus vehicle, +p < 0.05 versus
lazabemide. e Coronal sections
showing regions of interest for
ex vivo neurochemical analysis of
monoamines following vehicle,
moclobemide, and lazabemide
administration. dmPFC
dorsomedial PFC, OFC
orbitofrontal cortex, dmS
dorsomedial striatum, NAcb
nucleus accumbens, BLA
basolateral amygdala, CA1
hippocampal CA1 region, LH
lateral hypothalamus, DRN dorsal
raphé nuclei. Adapted from
Paxinos and Watson (2013)
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exploratory finding of a positive relationship between persev-
eration and plasma 5-HT suggests a possible reciprocal rela-
tionship between peripheral and central measures of 5-HT
function underlying natural variation in behavioral flexibility.
Thus, in a recent study, rats stratified for high and low persev-
erations on an identical spatial reversal task exhibited reduced
indices of serotonergic transmission in the DRN and OFC
(Barlow et al. 2015). However, the exact mechanisms under-
lying the apparently opponent relationship between plasma
and brain 5-HT remain unclear and would require further
studies to directly contrast plasma 5-HT levels with task-
related changes in extracellular 5-HT in the brain, in addition
to assessing platelet MAO activity (Arrojo et al. 2007).
Using the same paradigm as the present study, we recently
reported that high trait-like perseveration in rats is associated
both with decreased MAO-A and MAO-B expressions in the
dorsal raphé nucleus and increased MAO-A and MAO-B ex-
pression in the lateral OFC (Barlow et al. 2015). Highly per-
severative animals exhibited reduced 5-HTmetabolism and 5-
HT2A receptors in the OFC compared with low-perseverative
rats (Table 4). In the present study, the selective MAO-A in-
hibitor moclobemide, but not the MAO-B inhibitor
Table 3 Levels of DA and 5-HT in regions of interest following vehicle (Veh, n = 5), lazabemide (L10, n = 6), and moclobemide (M3, n = 4; M16,
n = 4) administration
Brain region Drug 5HT DA NA 5HIAA DOPAC
BLA Veh 0.28 (0.24) 2.39 (1.13) 0.63 (0.20) 3.06 (0.39) 4.36 (0.68)
L10 0.34 (0.22) 2.78 (1.03) 0.81 (0.18) 2.13 (0.35) 4.53 (0.62)
M3 2.66 (0.27)**,*** 9.45 (1.26)**,*** 1.17 (0.22) 1.37 (0.43)* 1.80 (0.76)
M16 2.57 (0.27)**,*** 9.64 (1.26)**,*** 1.07 (0.22) 0.83 (0.43)**,*** 1.35 (0.76)***
dmPFC Veh 0.39 (0.17) 0.44 (0.47) 1.25 (0.22) 1.67 (0.39) 0.71 (0.32)
L10 0.62 (0.16) 0.90 (0.43) 1.74 (0.20) 1.57 (0.35) 0.86 (0.29)
M3 1.97 (0.19)**,*** 1.66 (0.53) 2.03 (0.25) 1.15 (0.43) 0.89 (0.36)
M16 2.20 (0.19)**,*** 2.25 (0.53) 2.62 (0.25)** 0.77 (0.43) 1.27 (0.36)
dmS Veh 0.29 (0.08) 39.97 (5.78) 12.92 (1.34)
L10 0.40 (0.07) 53.03 (5.27) 14.44 (1.23)
M3 0.86 (0.09)**,*** 81.71 (6.46)**,*** 6.55 (1.50)*,***
M16 1.15 (0.09)**,*** 83.11 (6.46)**,*** 6.84 (1.50)***
DRN Veh 0.46 (1.35) 0.80 (0.28) 2.69 (1.08) 6.37 (0.39) 7.85 (3.57)
L10 0.89 (1.23) 0.66 (0.25) 4.05 (0.99) 6.66 (0.35) 0.96 (3.26)
M3 12.56 (1.51)**,*** 1.94 (0.31)*** 9.11 (1.21)*,*** 3.52 (0.43) 0.74 (3.99)
M16 13.93 (1.51)**,*** 1.50 (0.31) 9.63 (1.21)**,*** 2.76 (0.43)*** 1.16 (3.99)
Hippo Veh 1.72 (0.22) 0.21 (0.62) 2.86 (0.39) 1.68 (0.39) 2.03 (0.54)
L10 0.57 (0.18) 1.22 (0.56) 2.47 (0.36) 1.65 (0.35) 2.14 (0.49)
M3 1.70 (0.22) *,*** 0.10 (0.69) 3.54 (0.44) 0.96 (0.43) 0.58 (0.60)
M16 1.75 (0.22) *,*** 0.07 (0.69) 3.24 (0.44) 1.01 (0.43) 1.18 (0.60)
lH Veh 0.19 (0.69) 0.22 (0.14) 3.26 (1.00) 2.26 (0.39) 2.76 (0.95)
L10 0.29 (0.63) 0.34 (0.13) 4.13 (0.91) 2.43 (0.35) 1.35 (0.86)
M3 4.97 (0.77)**,*** 1.72 (0.16)**,*** 7.77 (1.11) 1.77 (0.43) 1.31 (1.06)
M16 5.08 (0.77)**,*** 2.51 (0.16)**,*** 10.92 (1.11)**,*** 1.38 (0.43) 0.75 (1.06)
lOFC Veh 0.06 (0.12) 0.46 (0.24) 0.76 (0.18) 1.91 (0.39) 3.66 (1.11)
L10 0.09 (0.11) 0.33 (0.22) 0.74 (0.16) 1.32 (0.35) 1.22 (1.01)
M3 1.85 (0.13)**,*** 0.88 (0.38) 1.74 (0.20)*,*** 1.37 (0.43) 3.47 (1.24)
M16 1.98 (0.13)**,*** 1.36 (0.27) 2.15 (0.20)**,*** 1.12 (0.43) 0.78 (1.24)
NAcc Veh 0.23 (0.09) 24.38 (3.74) 1.23 (0.39) 15.89 (0.99)
L10 0.26 (0.08) 27.63 (3.42) 1.15 (0.35) 12.82 (0.91)
M3 0.92 (0.10)**,*** 47.03 (4.18)**,*** 0.85 (0.43) 7.10 (1.11)**,***
M16 1.17 (0.10)**,*** 58.40 (4.18)**,*** 0.71 (0.43) 6.39 (1.11)**,***
Following a significant two-way interaction between region and drug treatment, Bonferroni-corrected post hoc comparisons were carried out to compare
treatment effects within each brain region
*p < 0.05; **p < 0.005 versus vehicle (BVeh^); ***p < 0.05 versus lazabemide (BL10^)
Psychopharmacology
lazabemide, significantly reduced the total number of trials
and total errors animals made before they achieved the set
criteria for reversal. Although both doses of moclobemide
improved general reversal performance, only the highest dose
(16 mg/kg) reduced the proportion of perseverative errors.
Notably, the higher dose of moclobemide also prominently
increased the time rats took to initiate a new trial following
an incorrect response but not following a correct response.
Similarly, only the high dose of moclobemide increased the
probability of high- but not low-perseveration rats to change
their response following an incorrect trial. These selective
effects on trial outcome tend to rule out mechanisms relating
to hyperactivity, a consequence of MAO inhibition
(Barbelivien et al. 2001), and may instead indicate increased
behavioral resilience to the negative feedback of non-reward
or to error monitoring processes often associated in humans
with the anterior cingulate cortex (via Berror-related
negativity^), which is also elevated in patients with OCD
(Endrass and Ullsperger 2014).
The neural mechanism underlying the improvement in
behavioral indices of cognitive flexibility by moclobemide
is unclear but parsimoniously may involve a facilitation in
serotonergic transmission in several other brain regions in-
cluding the OFC and amygdaloid complex (Clarke et al.
2005, 2011; Izquierdo et al. 2016; Rygula et al. 2010).
Reversible MAO-A inhibition profoundly increased 5-HT
(and NA) content in every region assayed, including the
DRN, BLA, and lateral OFC. Changes in DA content were
less consistent, however, with significant increases evident
only in the BLA and striatum. Central 5-HT plays a critical
role in adaptive responses to aversive and threatening stimuli
(Cools et al. 2008; Dayan and Huys 2009; Deakin and
Graeff 1991) and low levels of 5-HT produced by acute
dietary tryptophan depletion lead to negatively-biased deci-
sion-making (Cools et al. 2008; Rogers et al. 2003). In rats,
5-HT exerts complex effects on reward sensitivity and neg-
ative feedback (Bari et al. 2010; Rygula et al. 2015). For
instance, acute 5-HT reuptake inhibition with a high dose of
citalopram (10 mg/kg) decreased the sensitivity of rats to
negative feedback in a probabilistic reversal learning task
and facilitated behavioral flexibility (Bari et al. 2010), while
the same dose was found to improve behavioral flexibility
on a spatial reversal learning task (Barlow et al. 2015).
However, it is less clear how the reported effects of
moclobemide on reversal learning relate to measures of anx-
iety. While MAO-A inhibition produces anxiolytic effects in
rats (Caille et al. 1996; Eroğlu and Güven 1998), both acute
activation of the serotonergic dorsal raphé nucleus (Urban
et al. 2015) and acutely administered selective 5-HT inhibi-
tors (Birkett et al. 2011; Mombereau et al. 2010) increase
anxiety. These findings thus suggest that the anxiolytic ef-
fects of MAO-A inhibitors, including moclobemide, are un-
likely to be due to acute increases in 5-HT transmission and
implicate as a result other neurotransmitter systems in this
effect, including NA (see Eroğlu and Güven 1998). Since
low anxiety was associated with high trait-like levels of
perseveration, it is unlikely that moclobemide, with pre-
sumed anxiolytic effects, improved reversal learning by re-
ducing anxiety.
Although citalopram and moclobemide both facilitated re-
versal performance, the effect size of moclobemide was sig-
nificantly larger than that of citalopram (compare Barlow et al.
2015). This difference may be explained by the effects of
SSRIs to simultaneously exert biphasic inhibitory and facili-
tating effects on 5-HT transmission through blockade of 5-HT
reuptake and activation of inhibitory somatodendritic 5-HT1A
autoreceptors in the DRN (Sprouse and Aghajanian 1987).
Thus, high doses of citalopram have the effect of increasing
extracellular levels of 5-HT in the PFC, as measured by
in vivo microdialysis (Invernizzi et al. 1992) but not at lower
doses, which activate inhibitory 5-HT autoreceptors and di-
minish the activity of serotonergic neurons in the DRN
(Gardier et al. 1996). In contrast, MAO-A inhibition does
not affect the function of 5-HT autoreceptors, even after
long-term administration, (Blier et al. 1988), and consistently
increases 5-HT levels by inhibiting its decomposition
(Kumagae et al. 1991; Stahl 2015). Thus, unlike citalopram
that dose-dependently impairs and improves reversal learning
(Bari et al. 2010), moclobemide apparently exerts monophasic
effects on 5-HT transmission and strongly promotes behavior-
al flexibility.
In addition to its effects on 5-HT, MAO-A inhibition also
increased NE levels in the lateral OFC, PFC, and DRN.While
some studies report that acute NE reuptake inhibition and α-
2A receptor activation improves intradimensional (ID) rever-
sal performance (Seu and Jentsch 2009; Steere and Arnsten
1997), other studies using similar manipulations report effects
on extradimensional reversal learning (e.g., Bradshaw et al.
2016). Moreover, central NE depletion did not impair perfor-
mance on a taste/tactile reversal task (Jarbe et al. 1988) and
Table 4 Lose-shift probabilities for high (n = 5) and low (n = 5)
perseveration rats that received moclobemide (16 mg/kg, 3 mg/kg),
combination of lazabemide and moclobemide, and vehicle
Perseveration Condition Pr(shift|loss) ± SEM
High Moclobemide 16 0.68 ± (0.08)*,**
Moclobemide 3 0.55 ± (0.04)**
Combination 0.38 ± (0.05)
Vehicle 0.45 ± (0.06)
Low Moclobemide 16 0.55 ± (0.08)
Moclobemide 3 0.68 ± (0.04)
Combination 0.50 ± (0.05)*
Vehicle 0.60 ± (0.06)
*p < 0.05 versus vehicle; **p < 0.05 versus drug combination
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NE efflux increased only weakly in the rat medial PFC during
the reversal phase of a serial reversal learning task (Van Der
Meulen et al. 2007), suggesting that NEmay be less important
for behavioral adaptation following changing stimulus-reward
contingencies than for general attentional processes needed
for successful set-shifting (Cain et al. 2011; Tait et al. 2007;
Totah et al. 2015).
Contrasting with the effects of moclobemide, selective
MAO-B inhibition with lazabemide produced no significant
effects on task performance nor did this compound affect tis-
sue levels and turnover of 5-HT, DA, and NE in a number of
cortical and subcortical regions. These negative findings were
very unlikely to be due an insufficient dose of lazabemide
since much lower doses were reported to inhibit ex vivo
MAO-B activity by over 80% while leaving MAO-A activity
unaffected (2mg/kg (Henriot et al. 1994); 1 mg/kg (Jolkkonen
et al. 2000)). Moreover, the selected high dose of lazabemide
(10 mg/kg) has been shown to produce robust behavioral ef-
fects in other settings (Maki et al. 2000). Rather, the absence
of significant effects of lazabemide in the present study is
more consistent with its high selectivity for the MAO-B sub-
type that preferentially targets trace amines (Shih and
Thompson 1999). The singular contribution of MAO-A inhi-
bition to promoting behavioral flexibility was confirmed by
the combination treatment of moclobemide and lazabemide,
which mimicked the effects of moclobemide alone.
In conclusion, our findings demonstrate that selective and
reversible inhibition of MAO-A but not MAO-B activity
enhances behavioral indices of cognitive flexibility regard-
less of baseline flexibility on a spatial-discrimination rever-
sal learning task. Our results show, apparently for the first
time, that natural variation in behavioral flexibility is partly
predicted by reduced measures of trait-like anxiety and in-
creased plasma levels of 5-HT. Since cognitive flexibility is
impaired in OCD (Watkins et al. 2005) and unaffected first-
degree relatives of OCD patients (Chamberlain et al. 2007),
the index of perseveration used in the present study may
represent an endophenotype to support a deeper understand-
ing of etiological mechanisms in OCD and related disorders.
Our findings specifically implicate MAO-A in modulating
cognitive flexibility and encourage further investigations of
this ubiquitous enzyme as a target for diagnosis and
treatment.
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